According to the recent report by IMARC Group, titled “Intrauterine Devices (IUD) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,” the global intrauterine devices market reached a value of US$
4.3 Billion in 2022. Intrauterine devices (IUDs) are small T-shaped contraceptive devices which are placed in the uterus to prevent the implantation of fertilized ova. They are a form of long-acting reversible contraceptives (LARC) which help in birth control. IUDs can last for an extended period of 5 to 10 years, depending on the type. The hormones or copper in these devices change the cervical mucus lining, which prevents pregnancy. These devices have gained immense traction over the past decade due to the minimal side effects and discomfort associated with them. Moreover, they are highly cost-effective and available at efficient rates, making them more preferable over other methods of contraception.
Global Intrauterine Devices (IUD) Market Trends:
Growing rates of unintended pregnancies and unplanned births across the globe have increased the awareness among women regarding the benefits of contraceptive devices like IUDs as a precautionary measure. In confluence with this, several governments and non-profit organizations have taken initiatives to inform the masses about family planning, the advantages of contraceptives, and the health issues caused by unexpected pregnancies, which, in turn, is providing a thrust to the market growth. For instance, The International Federation of Gynaecology and Obstetrics (FIGO) is working toward improving women’s health by addressing the high maternal mortality rates in low resource countries. It is also encouraging women to make informed decisions about effective contraceptive methods. Furthermore, manufacturers are innovating with their products and have introduced advanced variants like slimmer and reusable IUDs. For instance, the copper IUD does not alter the hormone levels in a woman’s body. Moreover, it has an extremely low risk of ectopic pregnancy. As a result, it is gaining popularity among nulliparous women and adolescents. On account of these factors, the market is expected to reach US$
5.7 Billion by 2028, witnessing a CAGR of
4.75% during 2023-2028.
- Based on the product, hormonal IUDs represent the most popular type.
- On the basis of the end use, the market has been segmented into community healthcare, hospitals, gynecology clinics, and others.
- Region-wise, the market has been divided into Europe, North America, Asia Pacific, Middle East and Africa, and Latin America
- The competitive landscape of the market has been examined, with some of the key players being Actavis, Bayer, Teva Pharmaceuticals, Allergan, Eurogine, OCON Medical, Pregna, HLL Lifecare, HRA Pharma, ANI Pharmaceuticals, Besins HealthCare and SMB.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Phone No: (D) +91 120 433 0800 | www.imarcgroup.com
Americas :- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331